Regenerative Therapies for Osteoarthritis Industry 2021

 Osteoarthritis is a degenerative joint disorder and one of the leading cause of disability in geriatric population. Osteoarthritis is a challenging disease due to the deprived self-healing capacity and lack of specific diagnostic biomarkers. 

To know more 

There are limited treatment options available for the osteoarthritis which includes pain killer and anti-inflammatory medications, however no medications are available to heal the cartilage damage in the osteoarthritis patients. Regenerative medicine is a revolutionized area of medicine in which damaged tissue or organs are replaced with the patient’s own regenerated tissues in order to initiate natural healing process. Thus, many of the researchers are focusing on the development of regenerative medication effective for osteoarthritis such as monoclonal antibody against β-nerve growth factor and recombinant human fibroblast growth factor-18.

The prime growth driver for the global regenerative therapies for osteoarthritis market is increasing population with orthopedic disease and poor availability of effective medication for osteoarthritis. In North America, ~10% of men and 13% of women aged above 60 years are suffering from osteoarthritis. Also, the number of population affected with osteoarthritis is expected to increase due to growing obese population across the globe. In addition, government support for treatment of orthopedic diseases is increasing owing to the implementation of supportive legislative and policy initiatives. Furthermore, increasing demand for stem cell and tissue based research technologies and their products are also driving the growth for the global regenerative therapies for osteoarthritis market currently. However, availability of low cost alternatives such as open surgeries and synthetic drugs are few of the factors hampering the regenerative therapies for osteoarthritis market growth to some extent.